Back to Search
Start Over
Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults
- Source :
- Dermatology and Therapy
- Publication Year :
- 2017
- Publisher :
- Springer Science and Business Media LLC, 2017.
-
Abstract
- Introduction Dupilumab significantly improves signs and symptoms of atopic dermatitis (AD), including pruritus, symptoms of anxiety and depression, and health-related quality of life versus placebo in adults with moderate-to-severe AD. Since the cost-effectiveness of dupilumab has not been evaluated, the objective of this analysis was to estimate a value-based price range in which dupilumab would be considered cost-effective compared with supportive care (SC) for treatment of moderate-to-severe AD in an adult population. Methods A health economic model was developed to evaluate from the US payer perspective the long-term costs and benefits of dupilumab treatment administered every other week (q2w). Dupilumab q2w was compared with SC; robustness of assumptions and results were tested using sensitivity and scenario analyses. Clinical data were derived from the dupilumab LIBERTY AD SOLO trials; healthcare use and cost data were from health insurance claims histories of adult patients with AD. The annual price of maintenance therapy with dupilumab to be considered cost-effective was estimated for decision thresholds of US$100,000 and $150,000 per quality-adjusted life-year (QALY) gained. Results In the base case, the annual maintenance price for dupilumab therapy to be considered cost-effective would be $28,770 at a $100,000 per QALY gained threshold, and $39,940 at a $150,000 threshold. Results were generally robust to parameter variations in one-way and probabilistic sensitivity analyses. Conclusion Dupilumab q2w compared with SC is cost-effective for the treatment of moderate-to-severe AD in US adults at an annual price of maintenance therapy in the range of $29,000–$40,000 at the $100,000–$150,000 per QALY thresholds. Funding Sanofi and Regeneron Pharmaceuticals, Inc.
- Subjects :
- medicine.medical_specialty
Pediatrics
Cost effectiveness
Eczema
Dermatology
Dupilumab
Placebo
030207 dermatology & venereal diseases
03 medical and health sciences
0302 clinical medicine
Maintenance therapy
Quality of life
medicine
030212 general & internal medicine
health care economics and organizations
Original Research
Atopic dermatitis
Quality-adjusted life-years
business.industry
medicine.disease
Quality-adjusted life year
Economic evaluation
Physical therapy
Cost-effectiveness
Health economics
business
Subjects
Details
- ISSN :
- 21909172 and 21938210
- Volume :
- 7
- Database :
- OpenAIRE
- Journal :
- Dermatology and Therapy
- Accession number :
- edsair.doi.dedup.....1bdb3869000fa2da59e7993f6bd88a91